Animal models in preclinical trials of aspergillosis

Karl V. Clemons, Ph.D.
CIMR, SCVMMC, & Stanford Univ.
Why Perform Animal Models of Aspergillosis?

Studies on therapy

Monotherapy & Combination therapy:
AmB preps, azoles, echinocandins, etc.

Compare efficacies at same time!
Results similar among models and to clinical

Immunotherapy:
Various cytokines (interferon-\(\gamma\), TNF-\(\alpha\), GM-CSF, etc.), other immunomodulators,
Ablation of specific cytokines
The Ideal Animal Model

• No “warm fuzzy test tubes”!
  Should mimic clinical disease
• Should be standardized, reproducible & affordable!
• Parameters of survival and infectious burden controllable: define the model first!
• Wait until infection is established!
• Should reflect drug efficacy, toxicity and drug interactions similar to observed clinically
**Animal Models – Control of Variables**

<table>
<thead>
<tr>
<th>Animals – preclinical trial</th>
<th>Humans – clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syngeneic &amp; many strains --</td>
<td>No way</td>
</tr>
<tr>
<td>Age &amp; sex match --</td>
<td>Sort of</td>
</tr>
<tr>
<td>Control inocula &amp; route --</td>
<td>No way</td>
</tr>
<tr>
<td>Choice of inoculum strain --</td>
<td>No way</td>
</tr>
<tr>
<td>Control disease severity --</td>
<td>Sort of, but really no way</td>
</tr>
<tr>
<td>Control exp. duration –</td>
<td>Yes – if they show up</td>
</tr>
<tr>
<td>Survival &amp; CFU organs --</td>
<td>Survival – yes, CFU - no</td>
</tr>
<tr>
<td>Route &amp; duration of dosing --</td>
<td>Yes – to some degree</td>
</tr>
<tr>
<td>Control immunosuppression --</td>
<td>Yes – to some degree</td>
</tr>
<tr>
<td>Large #’s done at same time --</td>
<td>Limited # pts. &amp; time</td>
</tr>
<tr>
<td>Statistical analyses --</td>
<td>Yes – more difficult</td>
</tr>
<tr>
<td>Trials are prospective --</td>
<td>Some are - some are not</td>
</tr>
</tbody>
</table>
Animal Models of Aspergillosis

Primary model systems:
- Murine – systemic, pulmonary, CNS, ocular
- Rabbit – systemic, pulmonary, ocular
- Guinea pig – systemic, pulmonary
- Rat - systemic, pulmonary
- Bird – pulmonary

Normal or immunosuppressed - depends on model
Animal Models of Aspergillus

A. *fumigatus* is the most frequently used

Can test different *Aspergillus* species causing clinically relevant disease.

Clinically:

*A. terreus* increase frequency & AMB resistant

Models in rabbits and mice:
resistant to AMBs – like clinical
Saper, ICZ and POS effective

Models of Aspergillosis

• Need to be cautious interpreting results!

What looks good in one model may not look good in another model!
Models of Aspergillosis

• Systemic model
  – synergy between Mica and Nik Z

• Pulmonary model
  – NO synergy between Mica and Nik Z

Different models using same drugs may not give same result

Models of Aspergillosis

Use models for drug efficacy comparisons not likely to be done in a clinical trial

For example – is one lipid formulation of AmB superior for treatment of aspergillosis?
Summary - All Lipid AmB comparison
Systemic Aspergillosis

1. All formulations prolonged survival,
2. AmBi nearly equivalent to dAmB; ABCD and ABLC were less effective or equivalent depending on the severity
3. No survivors cured in both kidneys and brain
4. Each formulation efficacious, esp. in kidneys.
5. No lipid-formulation consistently superior to Fungizone even though higher doses given
6. All were equivalent to each other

Clemons and Stevens. AAC, 2004
Aspergillus Animal Models

Use models to look at new indications not possible in a clinical trial

Test efficacy of new and “old” drugs
• Alone – monotherapy
• Combination

Example – CNS aspergillosis
Monotherapy against CNS Aspergillosis

Amphotericin B
- dAmB, iv partially effective
- AmBisome or ABLC iv effective not curative

Azoles
- ICZ and VCZ PO partially effective
- POS very effective

Echinocandins
- Mica or CAS equally effective

NONE CURATIVE!
Aspergillus Animal Models

Use to examine combination therapies
Use to try regimens to achieve cure
CNS aspergillosis

Clinically, CNS disease a common site of dissemination. Poor response to treatments and high mortality.

CNS Model Objectives

• Examine combinations of antifungal drugs (AmBi, ABLC, dAmB, MICA, VCZ, ICZ, CAS) or escalating dosages
Combinations against CNS aspergillosis

- AmBi + echinocandins – improved survival, but no significant enhancement
- AmBi + VCZ – *significant enhancement*
- Sequential AmBi + VCZ ca. as effective as combination
- dAmB + CAS – indifferent
- Only combination regimens reduced CFU
- Only AmBi + VCZ caused significant reduction in brain and kidney
- No total cures were obtained

Combinations and CNS aspergillosis

- ABLC at 4 mg/kg = to higher dosages
  - more not better
- ABLC + echinocandins – improved survival, but ns.
  - (lower doses of combination equal to higher doses!)
- ABLC + ICZ – indifferent
- ABLC + VCZ – *significant enhancement*
- AmB + ICZ – slight enhancement?
- AmB + CAS – indifferent

Similar to results with AmBisome (Clemons et al. AAC, 2005)

Clemons et al. JAC, 2006
Combination Therapy Pulmonary Aspergillosis

In steroid-suppressed DBA/2 pulmonary model

- AmBi + VCZ, CAS, or Mica
- dAmB + Mica
- Mica + NikZ
- ICZ + Mica

*None better than monotherapy*
Aspergillus Animal Models

Cure, “The Holy Grail” of clinical medicine

Can you achieve cure
Using high doses?
Using combination therapy?

Is more better?
At what cost to tissues?
Achieving cure - systemic *Aspergillus*

Test AmBi, CAS, VCZ
- Dose-escalation
- Loading doses AmBi
- Combination AmBi + CAS or VCZ

No improvement in frequency of CURES!

Clemons, et al. AAC, 2005
Achieving cure for CNS Aspergillosis by dose-escalation

NO CURES & MORE IS NOT BETTER!

Clemons, et al. AAC, 2005
Achieving cure-
Systemic, Pulmonary or CNS *Aspergillus*

- More isn’t better and may be bad!
  - Increased dosages did not improve efficacy.
  - Dose-escalation of AmBi or ABLC may be deleterious
  - AmBi loading doses no improvement
- MICA or CAS – flat dose-response – 1 =10 mg/kg
- Suboptimal combo ≅ high dose AmBi or ABLC
- Sequential therapy not effective for cure
- No improvement in cure rate by any regimen
What about other filamentous fungi?

Increased frequency of zygomycosis

Treatments are poorly effective.

What works?
LAmB and echinocandin combination therapy against experimental mucormycosis

Ibrahim et al. 08 AAC:52:1556-8
LAmB + Mica or LAmB + Anidula: DKA mouse model

LAmB + Anidula
Enhanced survival
Less for CFU

LAmB + Mica
Enhanced survival & CFU

Ibrahim et al. 08 AAC:52:1556-8
LAmB +Anidula: Neutropenic mouse model

Ibrahim et al. 08 AAC:52:1556-8
What’s on the horizon for antifungals?

Azoles

• Isavuconazole (BAL-4815; Basilea)
  – Prodrug, active against *Candida* and *Aspergillus*

• Albaconazole (UR9825; Uriach)
  – broad spectrum

• Ravuconazole (BMS207147 or ER30346: Eisai)
  – broad spectrum

• ITF2534 (Italfarmaco)
  – broad spectrum, in vivo *Candida, Aspergillus Cryptococcus*

Pasqualotto and Denning, JAC, 2008; Clemons, et al ICAAC, 2008
What’s on the horizon for antifungals?

Polyenes

• Patricin A – (SPA-753)
  – *Candida* & *Cryptococcus* *in vivo*,
• New formulations of amphotericin B

Echinocandins

• Aminocandin (HMR-3270; Novexel)
  – *Candida* and *Aspergillus*

New classes

• Arylamidine (T-2307)
  • *Candida, Aspergillus, & Cryptococcus* (*Mitsuyama* et al AAC 2008)
• Sordarins??
Summary of animal models in preclinical trials aspergillosis

• Results provide a basis for running clinical trials of antifungal therapy for aspergillosis
• Have been the basis for treatment with AmBs, various azoles and echinocandins now approved for therapy
• Provide the rationale for potential clinical trial of various combination therapies
  – (e.g., liposomal AmB + VCZ, or CAS or MICA)
• Will be necessary to bring new drugs to trial